Subbarao Bondada

Subbarao Bondada, PhD, is a Professor in the Department of Microbiology, Immunology, and Molecular Genetics at the University of Kentucky College of Medicine, with joint appointments at the Markey Cancer Center and Toxicology program. His research integrates molecular oncology, immunology, and neurotoxicology to address critical challenges in cancer therapy.

His educational background includes a B.Sc. in Mathematics, Physics and Chemistry from Andhra Loyola College (India), M.Sc. in Chemistry from IIT Kanpur, and PhD from Tata Institute of Fundamental Research. Postdoctoral training was completed at the National Institutes of Health and Institute for Cancer Research.

Bondada's research focuses on two primary areas: (1) Chronic Lymphocytic Leukemia (CLL) mechanisms, investigating tonic BCR signaling, Par-4 tumor suppressor function, and IL-10-mediated immunosuppression; (2) Chemobrain pathogenesis, examining how extracellular vesicles carrying oxidized proteins trigger neurotoxic cytokine responses. His work employs murine transgenic models (Eµ-TCL1), human cell lines, and clinical collaborations at UK Medical Center.

Analysis of his 15 most recent publications reveals a strong trend toward translational research bridging basic mechanisms and therapeutic applications. Approximately 60% focus on CLL biology and immunotherapy resistance, while 40% investigate chemotherapy-induced cognitive impairment through oxidative stress and vesicle-mediated neuroinflammation. Key recurring themes include oxidative damage pathways, cytokine networks, and tumor microenvironment interactions.

Bondada actively mentors numerous graduate students and postdoctoral fellows, with consistent co-authorship patterns indicating robust trainee involvement in his NIH-funded projects. His collaborative network spans UK's Markey Cancer Center, Department of Toxicology, and external institutions including Cleveland Clinic and University of Cincinnati.

His laboratory investigates B-cell signaling pathways in leukemia using advanced techniques including flow cytometry, murine modeling, and extracellular vesicle characterization. Current work focuses on developing strategies to overcome IL-10-mediated immunosuppression in CLL and identifying biomarkers for early detection of chemotherapy-induced cognitive decline.